玻璃体腔抗血管内皮生长因子药物的心血管不良事件:随机临床试验的系统综述与荟萃分析
该系统综述与荟萃分析纳入74项随机临床试验,评估玻璃体腔抗VEGF药物相比非抗VEGF治疗在眼病患者中的全身不良事件。结果显示抗VEGF药物未增加主要心血管事件(OR 1.16,95%CI 0.85-1.58)或总死亡率(OR 1.27,95%CI 0.82-1.96),但糖尿病视网膜病变患者死亡风险增加(OR 1.80,95%CI 1.03-3.16),非眼部出血风险增加(OR 1.46,95%CI 1.01-2.10),主要见于AMD患者。
要点
- 抗VEGF药物未显著增加主要心血管事件或总死亡率。
- 糖尿病视网膜病变患者死亡风险增加,需关注。
- 非眼部出血风险增加,尤其AMD患者。
核心结论
- 玻璃体腔抗VEGF药物未增加主要心血管事件风险。
- 糖尿病视网膜病变患者死亡风险增加可能为安全信号但证据不强。
- 非眼部出血风险增加尤其AMD患者,需持续监测。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和Cochrane图书馆至2020年7月7日。
主要发现
- 抗VEGF药物 vs 对照:主要心血管事件OR 1.16(95%CI 0.85-1.58),总死亡率OR 1.27(95%CI 0.82-1.96)。
- 非眼部出血风险OR 1.46(95%CI 1.01-2.10),主要见于AMD患者。
关键数值与推荐
- 主要心血管事件定义未在摘要中详述。
- 非眼部出血为次要结局之一。
临床怎么用
- 抗VEGF治疗时需评估患者心血管风险,尤其糖尿病视网膜病变患者。
- AMD患者注意非眼部出血风险。
- 继续监测全身不良事件。
局限性
- 证据强度有限,安全性信号需进一步验证。
- 研究仅纳入随机临床试验,可能遗漏观察性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Systemic safety of intravitreal anti-vascular endothelial growth factor (anti-VEGF) is a matter of debate and regular updates are necessary. OBJECTIVE: To evaluate systemic adverse events (SAEs) associated with intravitreal anti-VEGF drugs compared with non-anti-VEGF treatments in patients with ocular diseases. DATA SOURCES: Electronic searches were conducted in MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases from inception to July 7, 2020. STUDY SELECTION: Randomized clinical trials conducted in adults with retinal diseases who received intravitreal anti-VEGF drugs. DATA EXTRACTION AND SYNTHESIS: Studies and treatment characteristics and outcome data were extracted and analyzed, and study quality was evaluated. MAIN OUTCOMES AND MEASURES: Main outcomes were major cardiovascular events (MACEs) and total mortality. Secondary outcomes included nonocular hemorrhage, components of MACEs, other cardiovascular outcomes, serious SAEs, and all SAEs. RESULTS: A total of 74 randomized clinical trials were analyzed: 32 trials (43%) included 14 190 patients with age-related macular degeneration (AMD), 24 (32%) included 5424 patients with diabetic retinopathy (diabetic macular edema or proliferative diabetic retinopathy), 17 trials (23%) included 3757 patients with retinal vein occlusion, and 1 trial (1%) included 122 patients with myopic choroidal neovascularization. Anti-VEGF drug administration did not increase MACEs compared with control agents (odds ratio [OR], 1.16; 95% CI, 0.85-1.58) or total mortality (OR, 1.27; 95% CI, 0.82-1.96). There was an interaction (subgroup difference, P = .04) in mortality risk depending on the underlying disease with an increase (OR, 1.80; 95% CI, 1.03-3.16; P = .04) in the risk of death in patients with diabetic retinopathy; however, no increase was observed in patients with AMD or retinal vein occlusion. Administration of anti-VEGF drugs increased the risk of nonocular hemorrhage (OR, 1.46; 95% CI, 1.01-2.10), mainly in patients with AMD. CONCLUSIONS AND RELEVANCE: Intravitreal anti-VEGF was not associated with an increase in MACEs in the trials examined herein. Increased mortality in patients with diabetes and nonocular hemorrhages, especially in those with AMD, could represent a safety signal, but the evidence was not strong. However, continued surveillance of SAEs remains warranted.
引用
- Ngo Ntjam N, Thulliez M, Paintaud G, et al. Cardiovascular Adverse Events With Intravitreal Anti-Vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Ophthalmol. 2021. PMID: 33856414. doi:10.1001/jamaophthalmol.2021.0640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。